Medindia

X

Immtech Investor Conference Call Scheduled for February 11, 2008

Thursday, February 7, 2008 General News J E 4
Advertisement
NEW YORK, Feb. 6 Immtech Pharmaceuticals, Inc.(Amex: IMM) will have an investor conference call on Monday, February 11,2008, at 4.30 PM (ET) to discuss its financial results for the quarter endedDecember 31, 2007 and to present an update on the Company's scientific andclinical progress. Investors and interested parties in the U.S. are invited tojoin the call by dialing (888) 338-8374 and callers outside the U.S. shouldcall (706) 902-3163. The User Access Code is # 2167994. To register, pleasecall no later than 10 minutes prior to the scheduled start of the call. Arecording of the conference call will be available on the Company's website(http://www.immtechpharma.com) from February 12, 2008 to February 29, 2008.

About Immtech Pharmaceuticals, Inc.

Immtech Pharmaceuticals, Inc. ("Immtech") is a pharmaceutical companyworking to commercialize drugs to treat infectious diseases and is expandingits targeted markets by applying its proprietary pharmaceutical platform totreat other disorders. Immtech has advanced clinical programs that include neworal treatments for pneumocystis pneumonia (PCP), trypanosomiasis (HAT orAfrican sleeping sickness), malaria and a well defined, expanding library ofcompounds targeting drug-resistant Gram-positive bacteria, fungal infections,Hepatitis C and other serious diseases. Immtech holds the exclusive worldwidelicenses to certain patents, patent applications and technology for productsderived from its proprietary pharmaceutical platform. For additionalinformation, please visit Immtech's website at http://www.immtechpharma.com.

This press release contains forward-looking statements regarding Immtech'sbusiness, including the future prospects for PCP. Except for historicalinformation, the matters discussed in this press release are forward-lookingstatements and are subject to risks and uncertainties. Actual results coulddiffer materially from these forward-looking statements. Factors that couldcause or contribute to such differences include, but are not limited to thefollowing: (i) Immtech's ability to develop commercially viable products; (ii)Immtech's ability to achieve profitability; (iii) Immtech's ability to retainkey personnel; (iv) the ability of Immtech's scientists and collaborators todiscover new compounds; (v) the availability of additional research grants;(vi) Immtech's ability to obtain regulatory approval of its drug candidates,including PCP; (vii) the success of Immtech's clinical trials; (viii)Immtech's dependence upon and contractual relationship with partners; (ix)Immtech's ability to manufacture or to contract with a third party tomanufacture its drug candidates at reasonable costs; (x) Immtech's ability toprotect its intellectual property; (xi) competition and alternativetechnologies; (xii) Immtech's ability to obtain reimbursement from third partypayers for any product it commercializes; and (xiii) Immtech's potentialexposure to significant product liability.

Additional risks are discussed in Immtech's current filings with theSecurities and Exchange Commission. Although Immtech believes the expectationsreflected in such forward-looking statements are based on reasonableassumptions, it can give no assurance that its expectations will be attained.The forward-looking statements are made as of the date of this press release,and Immtech undertakes no obligation to publicly update or revise anyforward-looking statement, whether as a result of new information, futureevents or otherwise, except as required by law.

SOURCE Immtech Pharmaceuticals, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
PRI Condemns PEPFAR Amendments
S
PCMA Applauds Secretary Leavitt's Support for Requ...